Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
45.1M
-
Number of holders
-
105
-
Total 13F shares, excl. options
-
25.7M
-
Shares change
-
+1.3M
-
Total reported value, excl. options
-
$339M
-
Value change
-
+$17.3M
-
Put/Call ratio
-
0.01
-
Number of buys
-
54
-
Number of sells
-
-37
-
Price
-
$13.15
Significant Holders of Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share (YMAB) as of Q3 2024
117 filings reported holding YMAB - Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share as of Q3 2024.
Y-mAbs Therapeutics, Inc. - Common stock, par value $0.0001 per share (YMAB) has 105 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 25.7M shares
of 45.1M outstanding shares and own 57.07% of the company stock.
Largest 10 shareholders include Paradigm Biocapital Advisors LP (4.09M shares), BlackRock, Inc. (3.03M shares), Sofinnova Investments, Inc. (2.19M shares), VANGUARD GROUP INC (2.04M shares), Polar Capital Holdings Plc (1.83M shares), Cormorant Asset Management, LP (1.45M shares), STATE STREET CORP (1.21M shares), Caligan Partners LP (1.2M shares), GEODE CAPITAL MANAGEMENT, LLC (813K shares), and Logos Global Management LP (800K shares).
This table shows the top 105 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.